Belong.Life Creates Conversational AI SaaS Solution to Support Cancer Clinical Trials

News
Article

Solution designed to accelerate the process of matching patients with eligible clinical trials.

System Artificial intelligence ChatGPT Chat Bot AI , Technology smart robot Ai Chat GPT application software , robot application Chat GPT. Generative AI. Image Credit: Adobe Stock Images/Ruslan Batiuk

Image Credit: Adobe Stock Images/Ruslan Batiuk

Belong.Life has officially launched Tara, a SaaS-based conversational AI cancer clinical trial matching platform for health providers and contract research organizations (CROs). According to the company, Tara is designed to accelerate the process of matching patients with eligible clinical trials, enabling increased recruitment at significantly lower costs. Following the launch of Dave, Tara is Belong’s second AI Health Mentor suite of solutions.

"Since our founding, Belong has provided clinical trial matching services to more than 30,000 patients," said Eliran Malki, CEO, co-founder, Belong.Life, in a company press release. "Tara is a natural extension of our services, helping to optimize clinical trial matching to benefit stakeholders with increased patient recruitment, improved randomization, and reduced costs and logistical challenges. Tara will enable more patients around the world to access clinical trials."

Reference: Belong.Life Launches New Conversational AI SaaS Solution for Cancer Clinical Trial Matching and Recruitment. PR Newswire. September 13, 2023. Accessed September 14, 2023. https://www.prnewswire.com/news-releases/belonglife-launches-new-conversational-ai-saas-solution-for-cancer-clinical-trial-matching-and-recruitment-301926197.html

Recent Videos
Related Content
© Crystal light - © Crystal light - stock.adobe.com.

Gilead’s Trodelvy Meets Primary Endpoint of Progression-Free Survival in Phase III ASCENT-03 Breast Cancer Study

Andy Studna, Senior Editor
May 28th 2025
Article

In patients with first-line metastatic triple-negative breast cancer who are not candidates for PD-1/PD-L1 inhibitors, Trodelvy (sacituzumab govitecan-hziy) achieved a statistically significant and clinically meaningful improvement in PFS compared to chemotherapy.

Unifying Industry to Better Understand GCP Guidance

Unifying Industry to Better Understand GCP Guidance

Andy Studna, Senior Editor
May 7th 2025
Podcast

In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.

© Dr_Microbe - © Dr_Microbe - stock.adobe.com

New Phase III Data Show Bayer’s Nubeqa Significantly Improves Quality of Life for Prostate Cancer Patients

Andy Studna, Senior Editor
May 27th 2025
Article

In a post-hoc analysis from the Phase III ARANOTE trial, new results show metastatic castration-sensitive prostate cancer patients treated with Nubeqa plus ADT experienced a clinically meaningful improvement in health-related quality of life and delayed pain progression.

Site Logo

Unlock Commercial Growth through Data-Driven Patient and HCP Insights Podcast

May 2nd 2025
Podcast
Credit: Dr_Microbe | stock.adobe.com. Conceptual image for prostate cancer treatment, 3D illustration showing destruction of a tumor inside prostate gland

ARCHES and ENZAMET Trials Confirm Long-Term Xtandi Efficacy in Metastatic Hormone-Sensitive Prostate Cancer

Davy James
May 23rd 2025
Article

Five- and eight-year trial data to be presented at ASCO demonstrate durable survival outcomes with Xtandi (enzalutamide) plus ADT, reinforcing its role as a frontline standard in metastatic hormone-sensitive prostate cancer.

© Pixel-Shot - © Pixel-Shot - stock.adobe.com

Roche’s Susvimo Lands FDA Approval for Diabetic Retinopathy Based on Phase III Pavilion Trial Data

Andy Studna, Senior Editor
May 22nd 2025
Article

One-year results from the Pavilion study showed patients who received Susvimo (ranibizumab) refilled every nine months achieved superior improvements on the Diabetic Retinopathy Severity Scale.

© 2025 MJH Life Sciences

All rights reserved.